Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556000 | 0.85 | IDO1 (0.44) | KIF11TAAR1 | |
| SCHEMBL3901609 | 0.84 | KIF11 (0.50) | KIF11MAOBHDAC2AGXT | |
| SCHEMBL16894138 | 0.82 | MAOB (0.51) | KIF11MAOBAGXTTAAR1 | |
| SCHEMBL28266587 | 0.79 | ALDH1A1 (0.45) | MAOBHDAC2AGXTTAAR1 | |
| SCHEMBL3786331 | 0.79 | CYP3A4 (0.48) | KIF11TAAR1 | |
| SCHEMBL3903661 | 0.79 | KIF11 (0.61) | KIF11MAOBHDAC2AGXT | |
| SCHEMBL3804563 | 0.77 | TAAR1 (0.50) | HDAC2TAAR1DPP4 | |
| SCHEMBL3899696 | 0.76 | KIF11 (0.57) | KIF11MAOBHDAC2AGXT | |
| SCHEMBL4596164 | 0.74 | ALDH1A1 (0.42) | KIF11MAOBAGXT | |
| SCHEMBL3908682 | 0.74 | CYP3A4 (0.63) | KIF11MAOBHDAC2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885MAOB 2353/4885HDAC2 1216/4885 |
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885MAOB 2109/4885HDAC2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.